Mobile

A study to compare a new drug for Type 2 Diabetes to placebo (a placebo looks like the study drug but has no medicine) and to a treatment already available for Type 2 Diabetes

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003552-21

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate a dose-response relationship of once-weekly subcutaneous injections of LY2944876 on hemoglobin A1c (HbA1c) change from baseline, and from this dose-response relationship at 12 weeks determine which LY2944876 doses are superior to placebo in patients with T2DM inadequately controlled with diet and exercise alone or treated with a stable dose of metformin.

Critère d'inclusion

  • Diabetes Mellitus, Type 2

Liens